Precision development of neurology therapeutics has historically been challenging due to a lack of identified biomarkers and effective biomarker detection methods.

But new technology and approaches are making it now possible to develop a comprehensive biomarker strategy for a neurology clinical development program.

This white paper provides information on:

• Current gold standard neurology-specific biomarkers
• Accepted and novel technologies for neurology clinical trial biomarker analysis including methods for detection of CSF biomarkers in blood
• How to build a robust, multi-parameter biomarker strategy for more effective neurology therapeutic development